Skip to main content
. 2019 Jan 2;9(1):7. doi: 10.3390/metabo9010007

Figure 3.

Figure 3

Overview of metabolite changes occurring in MCF-7 breast cancer cells two days post dosing with palbociclib, fulvestrant or in combination. Fold change values for significantly dysregulated metabolites (p < 0.05) are reported in orange (increase) and blue (decrease).